Evidence map›Paper›PMID 27593859›Full record

ArticleYonsei medical journal2016

Arginase Inhibition Restores Peroxynitrite-Induced Endothelial Dysfunction via L-Arginine-Dependent Endothelial Nitric Oxide Synthase Phosphorylation.

Minh Cong Nguyen, Jong Taek Park, Yeong Gwan Jeon, Byeong Hwa Jeon, Kwang Lae Hoe, Young Myeong Kim, Hyun Kyo Lim, Sungwoo Ryoo

Open access · goldAbstract read
In one paragraph

Article in Yonsei medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. General View of Arachidonic Acid (AA) Metabolism.Reviews of physiology, biochemistry and pharmacology · 2027
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Virus-Induced Membrane Fusion in Neurodegenerative Disorders.Frontiers in cellular and infection microbiology · 2022
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Roles of eNOS in atherosclerosis treatment.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Minh Cong NguyenDepartment of Biology, College of Natural Sciences, School of Medicine, Kangwon National University, Chuncheon, Korea.
Jong Taek ParkDepartment of Anesthesiology and Pain Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Yeong Gwan JeonDepartment of Anesthesiology and Pain Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Byeong Hwa JeonInfectious Signaling Network Research Center, Department of Physiology, School of Medicine, Chungnam National University, Daejeon, Korea.
Kwang Lae HoeDepartment of New Drug Discovery and Development, Chungnam National University, Daejeon, Korea.
Young Myeong KimDepartment of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chuncheon, Korea.
Hyun Kyo LimDepartment of Anesthesiology and Pain Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. hyunkyolim@yonsei.ac.kr.
Sungwoo RyooDepartment of Biology, College of Natural Sciences, School of Medicine, Kangwon National University, Chuncheon, Korea. ryoosw08@kangwon.ac.kr.
Kangwon National University · KRYonsei University · KRChungnam National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePeroxynitrite plays a critical role in vascular pathophysiology by increasing arginase activity and decreasing endothelial nitric oxide synthase (eNOS) activity. Therefore, the aims of this study were to investigate whether arginase inhibition and L-arginine supplement could restore peroxynitrite-induced endothelial dysfunction and determine the involved mechanism. MATERIALS AND

methodsHuman umbilical vein endothelial cells (HUVECs) were treated with SIN-1, a peroxynitrite generator, and arginase activity, nitrite/nitrate production, and expression levels of proteins were measured. eNOS activation was evaluated via Western blot and dimer blot analysis. We also tested nitric oxide (NO) and reactive oxygen species (ROS) production and performed a vascular tension assay.

resultsSIN-1 treatment increased arginase activity in a time- and dose-dependent manner and reciprocally decreased nitrite/nitrate production that was prevented by peroxynitrite scavenger in HUVECs. Furthermore, SIN-1 induced an increase in the expression level of arginase I and II, though not in eNOS protein. The decreased eNOS phosphorylation at Ser1177 and the increased at Thr495 by SIN-1 were restored with arginase inhibitor and L-arginine. The changed eNOS phosphorylation was consistent in the stability of eNOS dimers. SIN-1 decreased NO production and increased ROS generation in the aortic endothelium, all of which was reversed by arginase inhibitor or L-arginine. N(G)-Nitro-L-arginine methyl ester (L-NAME) prevented SIN-1-induced ROS generation. In the vascular tension assay, SIN-1 enhanced vasoconstrictor responses to U46619 and attenuated vasorelaxant responses to acetylcholine that were reversed by arginase inhibition.

conclusionThese findings may explain the beneficial effect of arginase inhibition and L-arginine supplement on endothelial dysfunction under redox imbalance-dependent pathophysiological conditions.

Indexed as

AnimalsArginaseArginineEndothelium, VascularHumansHuman Umbilical Vein Endothelial CellsNitric OxideNitric Oxide Synthase Type IIIPeroxynitrous AcidPhosphorylationReactive Oxygen SpeciesVascular DiseasesArginaseArgininearginine methyl esterNitric OxideNitric Oxide Synthase Type IIINOS3 protein, humanPeroxynitrous AcidReactive Oxygen Speciesarginase inhibitionendothelial dysfunctionendothelial nitric oxide synthase phosphorylationL-argininenitric oxidePeroxynitrite

Identifiers

PMID27593859
PMCPMC5011263
OpenAlexW2510089156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.